RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix (TM) for the treatment of neuroendocrine tumors
Houston (TX U.S.), Courbevoie (France), Nov. 13, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. (a Texas-based clinical stage biotechnology company) and Orano Med (a nuclear biotechnology company) announced today that the United States Food & Drug …